Details of the Drug-Related molecule(s) Interaction Atlas

Sisomicin Drug Info

Siseptin; Sisomicin sulfate; Sisomicina [INN-Spanish]; Sisomicine; Sisomicine [INN-French]; Sisomicinum; Sisomicinum [INN-Latin]; Sisomin; Sisomycin; Sissomicin; X55XSL74YQ; sisomicin; 32385-11-8; BRN 1357913; C19H37N5O7; Antibiotic 66-40; Antibiotic 6640; Dehydrogentamicin Cla; Rickamicin; Sch 13475; Sch-13475; CHEBI:9169; D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl-(1-6)-O-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-; EINECS 251-018-2; UNII-X55XSL74YQ

Cross-matching ID

PubChem CID

36119

ChEBI ID

CHEBI:9169

CAS Number

CAS 32385-11-8

TTD Drug ID

DM92P0F

INTEDE Drug ID

DR2408

General Information of Drug (ID: DM92P0F)

Molecule-Related Drug Atlas

Molecule Type:

DME

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Metabolized By Aminoglycoside phosphotransferase (aph-Ib)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[2]
Tobramycin	DMUI0CH	Bacteremia	1A73	Approved	[2]
Kanamycin	DM2DMPO	Bacteremia	1A73	Approved	[2]
Dibekacin	DMTX0PZ	N. A.	N. A.	Phase 4	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Aminoglycoside phosphotransferase (aph-Ib)^{Main DME}	DE5WGIM	A0A075C7U3_CAMJU	Substrate	[1]

------------------------------------------------------------------------------------

References

1	Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7.
2	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.